Autoimmune neuromuscular junction disorders are rare. However, myasthenia gravis is
being increasingly recognised in people older than 50 years. In the past 5–10 years …

Antibodies to the acetylcholine receptor (AChR) have been recognized for over 40 years
and have been important in the diagnosis of myasthenia gravis (MG), and its recognition in …

Objective Patients with myasthenia gravis without acetylcholine receptor (AChR) or muscle-
specific kinase (MuSK) antibodies detected by radioimmunoprecipitation assays (RIAs) are …

Myasthenia gravis (MG) is a rare autoimmune disease that is potentially threatening for
patient life. Auto-antibodies targeting structures of the neuromuscular junction, particularly …

Background We aimed to evaluate the diagnostic accuracy of enzyme-linked
immunosorbent assay (ELISA) for anti-muscle specific tyrosine kinase (MuSK) antibody (Ab) …

The direct impact and sequelae of infections in children and adults result in significant
morbidity and mortality especially when they involve the central (CNS) or peripheral nervous …

Introduction: Although immunotherapies such as prednisone are effective in treating
myasthenic muscle weakness, their effect on resolution of myasthenic‐induced persistent …

Introduction: Myasthenia gravis (MG) is a prototypical autoimmune disease, characterized by
pathogenic autoantibodies targeting structures of the neuromuscular junction …

Background This study aimed to characterize juvenile myasthenia gravis in a national
population-based cohort in Norway, and to evaluate long-term outcome and potential …

Myasthenia gravis (MG) appears to have a similar incidence among adult populations
worldwide. However, epidemiological and phenotypic differences have been noted among …